Free Trial

Lantheus (LNTH) Competitors

$78.22
-0.78 (-0.99%)
(As of 05/24/2024 ET)

LNTH vs. RIOT, NEOG, QDEL, CLDX, NTLA, MYGN, OGN, BBIO, GKOS, and IONS

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Riot Platforms (RIOT), Neogen (NEOG), QuidelOrtho (QDEL), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Glaukos (GKOS), and Ionis Pharmaceuticals (IONS).

Lantheus vs.

Riot Platforms (NASDAQ:RIOT) and Lantheus (NASDAQ:LNTH) are both mid-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.

Riot Platforms presently has a consensus target price of $18.33, suggesting a potential upside of 76.73%. Lantheus has a consensus target price of $99.17, suggesting a potential upside of 26.78%. Given Lantheus' stronger consensus rating and higher probable upside, research analysts plainly believe Riot Platforms is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Riot Platforms
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lantheus
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

40.3% of Riot Platforms shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.4% of Riot Platforms shares are owned by insiders. Comparatively, 1.5% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Riot Platforms received 169 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.34% of users gave Riot Platforms an outperform vote while only 65.21% of users gave Lantheus an outperform vote.

CompanyUnderperformOutperform
Riot PlatformsOutperform Votes
497
67.34%
Underperform Votes
241
32.66%
LantheusOutperform Votes
328
65.21%
Underperform Votes
175
34.79%

In the previous week, Riot Platforms had 1 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Riot Platforms and 9 mentions for Lantheus. Riot Platforms' average media sentiment score of 1.08 beat Lantheus' score of -0.35 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Riot Platforms
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
4 Very Negative mention(s)
Neutral
Lantheus
6 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Riot Platforms has a net margin of 76.02% compared to Riot Platforms' net margin of 33.72%. Riot Platforms' return on equity of 54.10% beat Lantheus' return on equity.

Company Net Margins Return on Equity Return on Assets
Riot Platforms76.02% 12.56% 11.66%
Lantheus 33.72%54.10%25.70%

Lantheus has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Riot Platforms$280.70M10.67-$49.47M$0.8711.92
Lantheus$1.30B4.18$326.66M$6.5511.94

Riot Platforms has a beta of 4.19, suggesting that its stock price is 319% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Summary

Riot Platforms beats Lantheus on 10 of the 18 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.42B$3.29B$5.19B$8.06B
Dividend YieldN/A0.70%2.83%3.93%
P/E Ratio11.94154.36150.2018.04
Price / Sales4.1877.302,462.6680.23
Price / Cash12.0617.0136.2131.61
Price / Book5.733.695.434.60
Net Income$326.66M$32.98M$106.11M$214.07M
7 Day Performance-1.82%-2.90%-1.32%-1.08%
1 Month Performance19.95%2.27%2.76%3.20%
1 Year Performance-18.77%-27.56%3.38%7.84%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RIOT
Riot Platforms
3.2334 of 5 stars
$10.61
-3.2%
$18.33
+72.7%
-8.0%$3.06B$280.70M12.20534
NEOG
Neogen
2.9159 of 5 stars
$13.37
-2.2%
$22.50
+68.3%
-22.0%$2.90B$822.45M1,338.342,640Positive News
QDEL
QuidelOrtho
4.2747 of 5 stars
$41.35
-2.5%
$59.00
+42.7%
-51.2%$2.77B$3.00B-1.577,100
CLDX
Celldex Therapeutics
0.8082 of 5 stars
$37.67
-0.2%
$66.00
+75.2%
+15.3%$2.48B$6.88M-13.22160
NTLA
Intellia Therapeutics
3.4785 of 5 stars
$25.71
-0.7%
$66.77
+159.7%
-40.5%$2.48B$36.28M-4.80526
MYGN
Myriad Genetics
2.8499 of 5 stars
$24.38
-2.5%
$25.57
+4.9%
+1.0%$2.21B$753.20M-8.652,700
OGN
Organon & Co.
4.2562 of 5 stars
$21.84
+0.3%
$22.60
+3.5%
+4.4%$5.62B$6.35B5.3410,000Positive News
BBIO
BridgeBio Pharma
4.4443 of 5 stars
$29.28
-0.8%
$47.67
+62.8%
+110.2%$5.48B$9.30M-9.09550Analyst Revision
GKOS
Glaukos
3.2043 of 5 stars
$108.49
-0.7%
$108.64
+0.1%
+92.1%$5.46B$314.71M-37.67907Analyst Forecast
Analyst Revision
IONS
Ionis Pharmaceuticals
4.6285 of 5 stars
$37.37
-3.5%
$59.54
+59.3%
-9.7%$5.45B$788M-14.00927

Related Companies and Tools

This page (NASDAQ:LNTH) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners